Universal Cells Inc.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Boehringer Ingelheim Acquires Nerio The

Astellas Pharma, Inc. will book an impairment loss totalling JPY58.3bn ($437m) in the fourth quarter of its fiscal year just ended on 31 March, in a decision set to dent its previously forecast profi

Sentiments around the 2023 biopharma dealmaking environment may be mixed, but Mike Luther, the global head of search and evaluation business development at Astellas Pharma, Inc. , hopes the coming ye

Eisai Co., Ltd. has decided to shut down its US research subsidiary H3 Biomedicine Inc in September as part of a wider restructuring of its global R&D organization. According to an official notice